CENTURY THERAPEUTICS INC

Insider buying at Century Therapeutics shows execs betting big on stem‑cell cancer therapy, sparking a 285% rally and a bullish investor buzz.

Century Therapeutics insider sales show routine compliance, not a warning: Gregory’s modest June 8 sale and steady holdings suggest stable confidence amid preclinical gains and market volatility.

Century Therapeutics’ new director option grant signals board confidence in its adult stem‑cell pipeline, while modest insider sales hint at routine portfolio moves.

Century Therapeutics insider sales show routine tax‑management, not a crisis—investors still see strong leadership commitment and biotech growth potential.

Insider sales at Century Therapeutics are routine tax‑withholding moves, not a red flag—executive liquidity management keeps confidence high while the company’s growth prospects remain strong.

Century Therapeutics insider sales show routine liquidity moves, not big confidence signals. Focus on upcoming clinical milestones, not stock‑price swings.

CEO Brent Pfeiffenberger’s March 6 sale of Century Therapeutics shares signals a routine tax‑related move, not a sign of distress, while the company’s stem‑cell platform and growth prospects stay strong.

Insider sales reveal CEO Brent Pfeiffenberger’s routine tax‑and‑liquidity moves, showing steady long‑term confidence in Century Therapeutics’ stem‑cell growth.

Insider sale alert: Carr Douglas sells 323 shares of Century Therapeutics for $1.82—tax‑triggered, not a profit‑seeking move, yet signals long‑term confidence amid market volatility and a recent $135 million private placement.